PBH icon

Prestige Consumer Healthcare

79.23 USD
+0.48
0.61%
At close Dec 26, 4:00 PM EST
After hours
79.23
+0.00
0.00%
1 day
0.61%
5 days
-0.04%
1 month
-4.75%
3 months
11.04%
6 months
14.99%
Year to date
27.81%
1 year
28.35%
5 years
95.77%
10 years
125.28%
 

About: Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Employees: 570

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

76% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 25

12% more repeat investments, than reductions

Existing positions increased: 118 | Existing positions reduced: 105

6% more funds holding

Funds holding: 303 [Q2] → 322 (+19) [Q3]

2% more capital invested

Capital invested by funds: $3.58B [Q2] → $3.64B (+$67.3M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

2.9% less ownership

Funds ownership: 104.12% [Q2] → 101.21% (-2.9%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$95
20%
upside
Avg. target
$95
20%
upside
High target
$95
20%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
DA Davidson
Linda Bolton Weiser
38% 1-year accuracy
39 / 104 met price target
20%upside
$95
Buy
Maintained
11 Nov 2024

Financial journalist opinion

Based on 3 articles about PBH published over the past 30 days

Positive
Zacks Investment Research
11 hours ago
Should Prestige Consumer Stock Stay in Your Portfolio Right Now?
Investors remain optimistic about PBH stock due to its strong focus on brand building.
Should Prestige Consumer Stock Stay in Your Portfolio Right Now?
Positive
Zacks Investment Research
1 week ago
PBH or ABT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?
PBH or ABT: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
4 weeks ago
PBH or SYK: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
PBH or SYK: Which Is the Better Value Stock Right Now?
Positive
Zacks Investment Research
1 month ago
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
PBH vs. SYK: Which Stock Is the Better Value Option?
Neutral
Seeking Alpha
1 month ago
Prestige Consumer Healthcare Inc (PBH) Q2 2025 Earnings Call Transcript
Prestige Consumer Healthcare Inc (NYSE:PBH ) Q2 2025 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Phil Terpolilli - Vice President, Investor Relations Ron Lombardi - Chairman, President & Chief Executive Officer Chris Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer Susan Anderson - Canaccord Anthony Lebiedzinski - Sidoti & Co. Operator Good day, ladies and gentlemen, and welcome to Prestige Consumer Healthcare's Second Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Prestige Consumer Healthcare Inc (PBH) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise
Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business.
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise
Neutral
Zacks Investment Research
1 month ago
Prestige Consumer Healthcare (PBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Prestige Consumer Healthcare (PBH) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Prestige Consumer Healthcare (PBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Neutral
Zacks Investment Research
1 month ago
Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.07 per share a year ago.
Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates
Positive
Zacks Investment Research
2 months ago
PBH or SYK: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
PBH or SYK: Which Is the Better Value Stock Right Now?
Neutral
Zacks Investment Research
2 months ago
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
PBH vs. SYK: Which Stock Is the Better Value Option?
Charts implemented using Lightweight Charts™